If you have moderate-to-severe eczema in 2026, you have more treatment options than ever before. The landscape has expanded from topical steroids and immunosuppressants to targeted biologics, oral JAK inhibitors, and a growing list of non-steroidal topicals. The challenge is no longer finding a treatment — it is finding the right one.
This guide compares every major eczema treatment available in 2026, organized by treatment category, with honest assessments of efficacy, side effects, cost, and who each option fits best.
Quick Comparison: 2026 Eczema Treatments at a Glance
| Treatment | Type | Best For | Route | Key Advantage | Key Limitation |
|---|---|---|---|---|---|
| Dupixent | IL-4/IL-13 biologic | Moderate-severe AD | Injection (q2w) | Proven long-term safety & efficacy | Injection, conjunctivitis |
| Rinvoq (upadacitinib) | JAK1 inhibitor | Moderate-severe AD | Oral (daily) | Fastest itch relief, highest clearance | Boxed warning, lab monitoring |
| Cibinqo (abrocitinib) | JAK1 inhibitor | Moderate-severe AD | Oral (daily) | Oral convenience, strong efficacy | Boxed warning, lab monitoring |
| Adbry (tralokinumab) | IL-13 biologic | Moderate-severe AD | Injection (q2w) | Targeted IL-13 blockade | Lower efficacy vs Dupixent |
| Adquey (difamilast) | Topical PDE4i | Mild-moderate AD | Topical (BID) | Low sting/burn, safe for kids 2+ | Twice daily, mild-moderate only |
| Vtama (tapinarof) | Topical AhR agonist | Mild-moderate AD | Topical (QD) | Once daily, remittive effect | Adults only, folliculitis |
| Zoryve (roflumilast) | Topical PDE4i | Mild-moderate AD | Topical (QD) | Once daily, ages 6+ | Mild-moderate only |
| Eucrisa (crisaborole) | Topical PDE4i | Mild-moderate AD | Topical (BID) | Ages 3 months+ | Frequent stinging |
Systemic Treatments for Moderate-to-Severe Eczema
Dupixent (Dupilumab)
How it works: Dupixent is a monoclonal antibody that blocks interleukin-4 (IL-4) and interleukin-13 (IL-13), two key cytokines driving type 2 inflammation in atopic dermatitis. It was the first biologic approved for eczema (2017) and remains the most widely prescribed.
Efficacy: In pivotal trials, approximately 36–39% of patients achieved clear or almost clear skin (IGA 0/1) at 16 weeks, and about 51% achieved EASI-75 (75% improvement). Long-term data out to 5+ years confirms sustained efficacy and a favorable safety profile.
Dosing: 300 mg subcutaneous injection every 2 weeks (after loading doses).
Side effects: The main unique side effect is conjunctivitis (eye inflammation), occurring in approximately 10–15% of patients. Injection site reactions are common but generally mild.
Who it's best for: Dupixent is the default first-line biologic for most patients with moderate-to-severe eczema due to its long track record, safety data across adults and children (now approved down to age 6 months), and lack of boxed warnings. It is the conservative choice when safety is the top priority.
Rinvoq (Upadacitinib)
How it works: Rinvoq is an oral selective JAK1 inhibitor. JAK1 mediates signaling for multiple inflammatory cytokines involved in eczema, including IL-4, IL-13, IL-31 (the primary itch cytokine), and TSLP.
Efficacy: In head-to-head trials against Dupixent (Heads Up study), Rinvoq 30 mg demonstrated statistically superior skin clearance: 61% achieved EASI-75 at week 16 vs. 39% for Dupixent. It also provides the fastest itch relief of any systemic eczema therapy, with significant itch reduction within 1–2 days.
Dosing: 15 mg or 30 mg oral tablet once daily.
Side effects: Rinvoq carries an FDA boxed warning (class-wide for JAK inhibitors) regarding increased risk of serious infections, malignancy, major adverse cardiovascular events (MACE), and thrombosis. These risks were primarily observed in older patients with rheumatoid arthritis on a different JAK inhibitor (tofacitinib), and the absolute risk in younger eczema patients appears lower, but the warning applies to the entire class. Acne, upper respiratory infections, and elevated creatine kinase are also common.
Who it's best for: Patients under 65 who prioritize maximum efficacy and itch relief, prefer an oral medication over injections, and are willing to accept the theoretical safety risks of JAK inhibition with appropriate monitoring.
Cibinqo (Abrocitinib)
How it works: Like Rinvoq, Cibinqo is a selective JAK1 inhibitor but with a somewhat different binding profile and selectivity ratio.
Efficacy: In the JADE DARE trial (head-to-head vs. Dupixent), abrocitinib 200 mg showed faster onset of itch relief and comparable or superior skin clearance at early time points, though differences narrowed over longer follow-up. Approximately 48% achieved EASI-75 at week 12.
Dosing: 100 mg or 200 mg oral tablet once daily.
Side effects: Same boxed warning as Rinvoq. Additional specific concerns include nausea (particularly at treatment initiation), platelet count reduction, and herpes zoster reactivation.
Who it's best for: Similar population to Rinvoq — patients wanting an oral option with strong efficacy. Some dermatologists prefer abrocitinib for patients with significant itch who may not tolerate the acne side effect associated with upadacitinib.
Adbry (Tralokinumab)
How it works: Adbry selectively neutralizes IL-13 only (unlike Dupixent, which blocks both IL-4 and IL-13).
Efficacy: IGA 0/1 rates of approximately 16–22% at week 16 in the ECZTRA trials — lower than Dupixent in cross-trial comparisons. However, a meaningful proportion of patients achieve durable responses by week 32.
Dosing: 300 mg subcutaneous injection every 2 weeks.
Side effects: Conjunctivitis rates appear lower than Dupixent. Injection site reactions are common but mild.
Who it's best for: Patients who cannot tolerate Dupixent (e.g., persistent conjunctivitis) or prefer a purely IL-13-targeted approach. It is generally considered a second-line biologic after Dupixent.
Topical Treatments for Mild-to-Moderate Eczema
Topical Corticosteroids
Still the foundation of eczema treatment. Available in seven potency classes. For acute flares, mid-to-high potency steroids on the body provide rapid relief. For sensitive areas (face, groin, eyelids), low-potency steroids or non-steroidal alternatives are preferred. Long-term continuous use of potent topical steroids risks skin atrophy, striae, and topical steroid withdrawal.
Adquey (Difamilast) — NEW in 2026
The newest non-steroidal topical option. A PDE4 inhibitor applied twice daily, approved for ages 2+. Its key advantage over Eucrisa is dramatically lower rates of application site stinging. For pediatric patients especially, this can make the difference between compliance and refusal. Read our full Adquey guide.
Vtama (Tapinarof)
An AhR agonist applied once daily for mild-to-moderate AD in adults. Vtama modulates immune function through a different pathway than PDE4 inhibitors, and clinical data suggests a "remittive effect" — some patients maintain improvement even after stopping treatment. The most common side effect is folliculitis (inflamed hair follicles).
Zoryve (Roflumilast Cream)
A PDE4 inhibitor applied once daily for mild-to-moderate AD in patients aged 6+. Its once-daily dosing is a convenience advantage over twice-daily Adquey and Eucrisa. Well-tolerated with low application site reaction rates.
Eucrisa (Crisaborole)
The original topical PDE4 inhibitor, approved for ages 3 months+. Effective but limited by its high rate of application site pain and burning (~29% of patients). With Adquey now available as a better-tolerated alternative, Eucrisa's main remaining advantage is its approval for infants as young as 3 months.
Calcineurin Inhibitors (Protopic, Elidel)
Tacrolimus (Protopic) and pimecrolimus (Elidel) have been mainstays for steroid-sensitive areas for over 20 years. They carry an FDA boxed warning regarding theoretical lymphoma risk, which has deterred some patients and providers despite no confirmed causative link. They remain useful options, particularly for facial and periorbital eczema.
2026 Eczema Treatment Algorithm
Here is a practical decision framework:
- Mild eczema, localized: Start with topical steroids (mid-potency for body, low-potency for face). For steroid-sparing maintenance, consider Vtama (adults), Zoryve (ages 6+), or Adquey (ages 2+).
- Mild-moderate, steroid-averse or steroid-dependent: Transition to non-steroidal topicals as primary therapy. Adquey or Zoryve are the best-tolerated options.
- Moderate-severe, first systemic: Dupixent is the default first-line biologic due to safety profile and broad approval. Rinvoq or Cibinqo are alternatives if the patient prefers oral therapy or needs faster itch control.
- Moderate-severe, Dupixent failure or intolerance: Switch to Rinvoq 30 mg (highest efficacy) or Cibinqo 200 mg. If JAK inhibitors are contraindicated, consider Adbry.
- Refractory eczema: Combination therapy (biologic + topical), clinical trial enrollment, or specialist referral.
Cost Comparison
| Treatment | List Price (est.) | With Insurance/Copay Program |
|---|---|---|
| Dupixent | ~$3,600/month | $0–$35/month (copay card) |
| Rinvoq | ~$5,800/month | $0–$15/month (copay card) |
| Cibinqo | ~$5,200/month | $0–$15/month (copay card) |
| Adbry | ~$3,500/month | $0–$25/month (copay card) |
| Adquey | ~$600–900/tube | $0–$35 (copay card, est.) |
| Vtama | ~$800/tube | $0–$35 (copay card) |
| Zoryve | ~$700/tube | $0–$35 (copay card) |
| Eucrisa | ~$700/tube | $0–$35 (copay card) |
| Generic topical steroids | $5–$50/tube | Low-cost generics widely available |
Most branded eczema medications offer copay assistance programs that dramatically reduce out-of-pocket costs for commercially insured patients. Medicare patients may face higher costs due to donut hole coverage gaps. Always check manufacturer websites for current savings programs.
The Bottom Line
The best eczema treatment in 2026 depends on severity, preferences, and individual risk tolerance. For mild-to-moderate eczema, the new generation of non-steroidal topicals (Adquey, Vtama, Zoryve) provides steroid-sparing options that are effective and well-tolerated. For moderate-to-severe disease, Dupixent remains the safest systemic, while Rinvoq offers the highest efficacy for patients willing to accept JAK inhibitor risks.
There is no single "best" treatment — there is the best treatment for you. Use the MedSwitcher comparison tool to compare eczema treatments side-by-side and discuss the results with your dermatologist.
Sources
- American Academy of Dermatology (AAD) Atopic Dermatitis Treatment Guidelines.
- Heads Up (upadacitinib vs dupilumab) and JADE DARE (abrocitinib vs dupilumab) trial results.
- Prescribing information for all referenced medications.
- MedSwitcher editorial analysis, April 2026.